The ongoing threat of respiratory infections, particularly from the novel coronavirus (SARS-CoV-2) and influenza, necessitates the development of rapid, reliable diagnostic tests. Among the leading Flu test kits in this space, the CorDx TyFast Flu A/B & COVID-19 Test stands out for its superior features.
This article provides an in-depth review of this test alongside other notable kits, such as LifeSign Status™, InBios Rapid Test, iHealth COVID-19/Flu A&B Rapid Test, Flowflex COVID-19 and Flu A/B Home Test, and CLINITEST Rapid COVID-19 Antigen Self-Test.
CorDx TyFast Flu A/B & COVID-19 Test
Overview
The CorDx TyFast Flu A/B & COVID-19 Test is a lateral flow immunochromatographic assay designed to detect and differentiate between influenza A, influenza B, and SARS-CoV-2 antigens. It uses highly sensitive monoclonal antibodies to capture these viral proteins from anterior nasal swab specimens. This test is authorized for emergency use by the FDA and is intended for use in CLIA-certified laboratories and point-of-care settings operating under a CLIA Certificate of Waiver.
Accuracy and Reliability
Sensitivity and Specificity
- SARS-CoV-2: Positive Percent Agreement (PPA) of 89.1% and Negative Percent Agreement (NPA) of 99.8%.
- Influenza A: PPA of 83.6% and NPA of 98.8%.
- Influenza B: PPA of 90.0% and NPA of 99.9%.
These high sensitivity and specificity rates ensure that the test accurately detects infections, minimizing the risk of both false positives and false negatives.
Ease of Use
The CorDx TyFast test includes user-friendly instructions and detailed guidance, making it accessible even for less experienced personnel. The process involves swabbing, mixing with the reagent, and reading the results on the test cassette within 10 minutes. The clear visual indicators on the cassette simplify result interpretation.
Regulatory Approval
The test is FDA-authorized for emergency use, emphasizing its reliability and effectiveness. It is suitable for various healthcare settings, including CLIA-certified laboratories and point-of-care locations with a CLIA Certificate of Waiver.
Interpretation of Results
Results are easy to interpret, with clear lines indicating the presence of SARS-CoV-2, influenza A, or influenza B. A red line in the control region confirms the test’s correctness.
Limitations and Considerations
While highly accurate, the CorDx TyFast Test does not differentiate between specific influenza subtypes or SARS-CoV-2 variants. However, its overall high sensitivity and specificity make it a reliable diagnostic tool.
LifeSign Status™
Overview
The LifeSign Status™ is a rapid antigen test for the simultaneous detection of influenza A, influenza B, and SARS-CoV-2. It uses lateral flow immunoassay technology to identify viral proteins in nasopharyngeal and anterior nasal swab specimens.
Accuracy and Reliability
Sensitivity and Specificity
- High specificity
- Lower sensitivity compared to molecular tests, leading to a potential for false negatives, particularly in early infection stages or asymptomatic individuals.
Ease of Use
The LifeSign Status™ test kit includes all necessary components for swabbing and testing. Results are available within 10-15 minutes, although the procedure may be cumbersome for inexperienced users.
Regulatory Approval
Authorized under the FDA’s Emergency Use Authorization (EUA), it is limited to use in CLIA-certified laboratories and specific point-of-care settings.
Interpretation of Results
Results appear as colored lines, which must be read within a specific timeframe, typically between 10 and 30 minutes. Careful timing and interpretation are essential.
Limitations and Considerations
The LifeSign Status™ test’s lower sensitivity can result in missed diagnoses, especially in asymptomatic individuals or those in early infection stages.
InBios Rapid Test
Overview
The InBios Rapid Test is a lateral flow immunochromatographic assay for detecting the SARS-CoV-2 nucleocapsid protein antigen in anterior nasal swab specimens. It is intended for symptomatic individuals and can be used in various settings.
Accuracy and Reliability
Sensitivity and Specificity
- PPA: 84.2%
- NPA: 99.8%
While it shows high specificity, its sensitivity is limited, resulting in potential false negatives.
Ease of Use
The test provides quick visual results within approximately 20 minutes, making it suitable for ease of use in non-laboratory settings.
Limitations and Considerations
The InBios Rapid Test is limited to detecting SARS-CoV-2, providing no information on other respiratory infections like influenza A and B.
iHealth COVID-19/Flu A&B Rapid Test
Overview
The iHealth COVID-19/Flu A&B Rapid Test detects and differentiates SARS-CoV-2, influenza A, and influenza B antigens. It is authorized for non-prescription home use with self-collected anterior nares nasal swab specimens.
Accuracy and Usability
The test is simple to use, involving swabbing, mixing, and dripping the sample into a test device, with results in about 15 minutes. However, its sensitivity is lower compared to molecular tests, requiring serial testing for accurate diagnosis.
Limitations and Considerations
The iHealth test does not differentiate between SARS-CoV and SARS-CoV-2 and is not intended to detect influenza C antigens. A full rundown comparison of this product is available at Cost Plus Med Tech here iHealth Covid Test vs. CorDx.
Flowflex COVID-19 and Flu A/B Home Test
Overview
The Flowflex COVID-19 and Flu A/B Home Test is an antigen test designed for qualitative detection of SARS-CoV-2, influenza A, and influenza B protein antigens. It is intended for home use, allowing for self-collection of samples.
Accuracy and Usability
Although easy to use, the test’s accuracy can vary based on user technique. It provides results in approximately 15 minutes but has a higher chance of false negatives, particularly with low viral loads.
Limitations and Considerations
Flowflex is designed for home use, which can result in user-dependent errors in sample collection and result interpretation.
CLINITEST Rapid COVID-19 Antigen Self-Test
Overview
The CLINITEST Rapid COVID-19 Antigen Self-Test is designed for the rapid detection of SARS-CoV-2 antigens in anterior nasal swab samples. It is intended for self-administration.
Accuracy and Reliability
The test claims a PPA of 85.4% and an NPA of 99.3%. While these figures suggest high specificity, the sensitivity may not be as reliable for detecting lower viral loads, leading to false negatives.
Usability
The test is designed for home use, requiring users to follow a series of steps for sample collection and result reading within 15 minutes.
Limitations and Considerations
The CLINITEST only detects SARS-CoV-2, which can be a limitation during flu season when symptoms overlap with influenza.
Conclusion
In the realm of rapid diagnostic tests for respiratory infections, the CorDx TyFast Flu A/B & COVID-19 Test stands out due to its high sensitivity, specificity, and ease of use. Its ability to accurately detect and differentiate between SARS-CoV-2, influenza A, and influenza B makes it a comprehensive tool for both clinical and point-of-care settings. While other tests like the LifeSign Status™, InBios Rapid Test, iHealth COVID-19/Flu A&B Rapid Test, Flowflex COVID-19 and Flu A/B Home Test, and CLINITEST Rapid COVID-19 Antigen Self-Test offer valuable solutions, they have limitations in terms of sensitivity, specificity, or the range of pathogens detected.
In the ever-evolving landscape of respiratory diagnostics, the CorDx TyFast Flu A/B & COVID-19 Test emerges as a frontrunner, providing healthcare professionals with a dependable tool for managing and controlling the spread of infectious diseases. By choosing the CorDx TyFast Test, healthcare providers can ensure timely and accurate results, ultimately contributing to better patient outcomes and public health.
